MO – Patient Worthy

New Resources Could Improve Drug Development for Fibrodysplasia Ossificans Progressiva

Post author:Trudy Horsting
Post published:March 4, 2019
Post category:Fibrodysplasia Ossificans Progressiva (FOP)Hereditary Multiple Osteochondromas Rare Disease Renal Cell Carcinoma

Ipsen has just announced that they will be acquiring Clementia Pharmaceuticals. This merging of companies is exciting for the rare community because it will strengthen the resources, knowledge-base, and overall…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More